PHI-501, a novel pan-RAF/DDRs dual kinase inhibitor, overcomes BRAF or MEK inhibitor resistance in melanoma

被引：0
|
作者：
Kim, Sue Min
Park, Jung Hee
Nam, Ky-Youb
Han, June H-J
Kim, Kyu-Tae
Yoon, Jeong Hyeok
Sengupta, Sandip
Sim, Taebo
Shin, Sang Joon
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2023-411
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
411
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Antitumor activity of KIN-2787, a next-generation pan-RAF inhibitor, in combination with MEK inhibition in preclinical models of human NRAS mutant melanoma.
    Miller, Nichol
    Wang, Tim Sen
    Lee, Catherine
    Severson, Paul
    Ke, Eugene
    Kobayashi, Ken
    Williams, Richard Thomas
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [42] Piperlongumine, a novel treatment option to overcome BRAF inhibitor resistance in melanoma
    Ramachandran, Sharavan
    Fofaria, Neel
    Srivastava, Sanjay
    CANCER RESEARCH, 2018, 78 (13)
  • [43] Inhibition of HSP90 by AT13387 Delays the Emergence of Resistance to BRAF Inhibitors and Overcomes Resistance to Dual BRAF and MEK Inhibition in Melanoma Models
    Smyth, Tomoko
    Paraiso, Kim H. T.
    Hearn, Keisha
    Rodriguez-Lopez, Ana M.
    Munck, Joanne M.
    Haarberg, H. Eirik
    Sondak, Vernon K.
    Thompson, Neil T.
    Azab, Mohammad
    Lyons, John F.
    Smalley, Keiran S. M.
    Wallis, Nicola G.
    MOLECULAR CANCER THERAPEUTICS, 2014, 13 (12) : 2793 - 2804
  • [44] Paradoxical activation and RAF inhibitor resistance of BRAF protein kinase fusions characterizing pediatric astrocytomas
    Sievert, Angela J.
    Lang, Shih-Shan
    Boucher, Katie L.
    Madsen, Peter J.
    Slaunwhite, Erin
    Choudhari, Namrata
    Kellet, Meghan
    Storm, Phillip B.
    Resnick, Adam C.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2013, 110 (15) : 5957 - 5962
  • [45] Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors
    Morris, Erick J.
    Jha, Sharda
    Restaino, Clifford R.
    Dayananth, Priya
    Zhu, Hugh
    Cooper, Alan
    Carr, Donna
    Deng, Yongi
    Jin, Weihong
    Black, Stuart
    Long, Brian
    Liu, Jenny
    DiNunzio, Edward
    Windsor, William
    Zhang, Rumin
    Zhao, Shuxia
    Angagaw, Minilik H.
    Pinheiro, Elaine M.
    Desai, Jagdish
    Xiao, Li
    Shipps, Gerald
    Hruza, Alan
    Wang, James
    Kelly, Joe
    Paliwal, Sunil
    Gao, Xiaolei
    Babu, Boga Sobhana
    Zhu, Liang
    Daublain, Pierre
    Zhang, Ling
    Lutterbach, Bart A.
    Pelletier, Marc R.
    Philippar, Ulrike
    Siliphaivanh, Phieng
    Witter, David
    Kirschmeier, Paul
    Bishop, W. Robert
    Hicklin, Daniel
    Gilliland, D. Gary
    Jayaraman, Lata
    Zawel, Leigh
    Fawell, Stephen
    Samatar, Ahmed A.
    CANCER DISCOVERY, 2013, 3 (07) : 742 - 750
  • [46] Upstream mitogen-activated protein kinase (MAPK) pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patients
    Goldinger, Simone M.
    Zimmer, Lisa
    Schulz, Carsten
    Ugurel, Selma
    Hoeller, Christoph
    Kaehler, Katharina C.
    Schadendorf, Dirk
    Hassel, Jessica C.
    Becker, Juergen
    Hauschild, Axel
    Dummer, Reinhard
    EUROPEAN JOURNAL OF CANCER, 2014, 50 (02) : 406 - 410
  • [47] Combining a novel dual RAF/MEK inhibitor with immunomodulation to promote an anti-tumor response
    Dong, Lauren
    Choi, Hyejin
    Budhu, Sadna
    Mehanna, Nezar
    Falik, Nouraiz
    Rosen, Neal
    Merghoub, Taha
    Wolchok, Jedd D.
    JOURNAL OF IMMUNOLOGY, 2020, 204 (01):
  • [48] COMBINING A NOVEL DUAL RAF/MEK INHIBITOR WITH IMMUNOMODULATION TO PROMOTE AN ANTI-TUMOR RESPONSE
    Dong, Lauren
    Choi, Hyejin
    Budhu, Sadna
    Schulze, Isabell
    Mehanna, Nezar
    Rosen, Neal
    Merghoub, Taha
    Wolchok, Jedd
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A634 - A634
  • [49] A phase I clinical trial evaluating exarafenib, a selective pan-RAF inhibitor in combination with binimetinib in NRAS-mutant (NRASMut) melanoma (Mel) & BRAF-altered solid tumors
    Cassier, P.
    Mehnert, J. M.
    Kim, R.
    Chmielowski, B.
    Millward, M.
    Perez, C. A.
    Gonzalez Cao, M.
    Gambardella, V.
    Mckean, M.
    Brose, M. S.
    Xing, Y.
    Long, G. V.
    Kelly, A.
    Lee, G.
    Severson, P.
    Williams, R.
    Marqueste, C. Gaudy
    ANNALS OF ONCOLOGY, 2024, 35 : S491 - S492
  • [50] Development of a dual inhibitor of pan-RAF and VEGFR2 for the treatment of metastatic colorectal cancer with mutant K-RAS
    Hong, Sungpyo
    Choi, Young-Il
    Choi, Jihye
    Kim, Wonyoung
    Kwon, Ho-Seok
    Park, Yong Bin
    Ki, Min-Hyo
    Shin, Hee Jong
    Lee, Michael
    Ahn, Soon Kil
    CANCER RESEARCH, 2016, 76
12345